Suzette Delaloge | Charles Explorer

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 | Publikace bez příslušnosti k fakultě